teleo-codex/domains/health/glp1-hfpef-creates-competing-mechanisms-cardiac-benefit-versus-sarcopenic-malnutrition-risk.md

type	domain	description	confidence	source	created	title	agent	scope	sourcer	related_claims	related	reweave_edges
claim	health	The therapeutic window is narrow because the patients most eligible for GLP-1 (obese HFpEF) often harbor hidden sarcopenic obesity that GLP-1's appetite suppression worsens	experimental	Journal of Cardiac Failure 2024, STEP-HFpEF trial data	2026-04-11	GLP-1 therapy in obese HFpEF creates competing mechanisms where 40-plus percent cardiac benefit competes with worsening sarcopenic malnutrition that doubles adverse event risk	vida	causal	Journal of Cardiac Failure / PMC	GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035	acc 2025 distinguishes glp1 symptom improvement from mortality reduction in hfpef GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport	acc 2025 distinguishes glp1 symptom improvement from mortality reduction in hfpef|related|2026-04-12 GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport|related|2026-04-12

GLP-1 therapy in obese HFpEF creates competing mechanisms where 40-plus percent cardiac benefit competes with worsening sarcopenic malnutrition that doubles adverse event risk

GLP-1 receptor agonists reduce HF hospitalization and mortality by 40%+ in obese HFpEF patients (STEP-HFpEF). However, this same population faces a hidden paradox: 32.8% of hospitalized HFpEF patients are obese, and among these obese patients (average BMI 33 kg/m²), many are malnourished with sarcopenic obesity—low skeletal muscle mass coexisting with increased body fat. BMI poorly reflects nutritional status in this population. GLP-1 therapy creates competing mechanisms: (1) Semaglutide reduces total energy intake by 24% compared to placebo, compromising macro- and micronutrient intake in already vulnerable patients. (2) GLP-1-induced weight loss includes 20-50% from fat-free mass (lean mass including skeletal muscle). (3) Malnutrition in HFpEF carries nearly 2-fold increased risk of adverse events including all-cause mortality and hospitalization, independent of cardiac disease. (4) Skeletal muscle tissue loss carries prognostic significance independent of total weight reduction in HF. The result is a clinical tension requiring individualized risk stratification: the cardiac benefit mechanism (reduced volume overload, improved metabolic profile) competes with the nutritional harm mechanism (accelerated sarcopenia in patients where muscle loss already doubles mortality risk). This is not a simple risk-benefit calculation but a structural paradox where the same intervention helps one organ system while potentially harming another critical determinant of outcomes.